Editorial
doi: 10.1001/jama.2018.12565.
Carbapenem-Sparing Therapy for Extended-Spectrum β-Lactamase-Producing E coli and Klebsiella pneumoniae Bloodstream Infection: The Search Continues
Affiliations
- PMID: 30208439
- DOI: 10.1001/jama.2018.12565
Item in Clipboard
Editorial
Carbapenem-Sparing Therapy for Extended-Spectrum β-Lactamase-Producing E coli and Klebsiella pneumoniae Bloodstream Infection: The Search Continues
JAMA.
.
No abstract available
Comment on
-
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.JAMA. 2018 Sep 11;320(10):984-994. doi: 10.1001/jama.2018.12163. JAMA. 2018. PMID: 30208454 Free PMC article. Clinical Trial.
Similar articles
-
Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.Diagn Microbiol Infect Dis. 2011 May;70(1):150-3. doi: 10.1016/j.diagmicrobio.2010.12.008. Epub 2011 Mar 12. Diagn Microbiol Infect Dis. 2011. PMID: 21398070
-
Predictors of mortality from community-onset bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.Infect Control Hosp Epidemiol. 2008 Jul;29(7):671-4. doi: 10.1086/588082. Infect Control Hosp Epidemiol. 2008. PMID: 18624669
-
Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.Antimicrob Agents Chemother. 2004 Dec;48(12):4574-81. doi: 10.1128/AAC.48.12.4574-4581.2004. Antimicrob Agents Chemother. 2004. PMID: 15561828 Free PMC article.
-
Cefoxitin as a carbapenem-sparing antibiotic for infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.Infect Dis (Lond). 2015;47(11):789-95. doi: 10.3109/23744235.2015.1062133. Epub 2015 Jul 2. Infect Dis (Lond). 2015. PMID: 26136072
-
Extended spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae: critical tools for antibiotic resistance pattern.J Basic Microbiol. 2017 Jun;57(6):460-470. doi: 10.1002/jobm.201700008. Epub 2017 Apr 11. J Basic Microbiol. 2017. PMID: 28397262 Review.
Cited by
-
Antimicrobial Stewardship Program for Patients in the Hematological Department Receiving Carbapenem Therapy: A Single-Center and Interrupted Time Series Analysis.Antibiotics (Basel). 2023 Feb 2;12(2):302. doi: 10.3390/antibiotics12020302. Antibiotics (Basel). 2023. PMID: 36830213 Free PMC article.
-
Best practices: Appropriate use of the new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa.S Afr J Infect Dis. 2022 Oct 20;37(1):453. doi: 10.4102/sajid.v37i1.453. eCollection 2022. S Afr J Infect Dis. 2022. PMID: 36338193 Free PMC article.
-
Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial.JAMA. 2022 Oct 4;328(13):1304-1314. doi: 10.1001/jama.2022.17034. JAMA. 2022. PMID: 36194218 Free PMC article. Clinical Trial.
-
A bla SIM-1 and mcr-9.2 harboring Klebsiella michiganensis strain reported and genomic characteristics of Klebsiella michiganensis.Front Cell Infect Microbiol. 2022 Aug 24;12:973901. doi: 10.3389/fcimb.2022.973901. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36093205 Free PMC article.
-
Efficacy and In Vitro Activity of Novel Antibiotics for Infections With Carbapenem-Resistant Gram-Negative Pathogens.Front Cell Infect Microbiol. 2022 May 20;12:884365. doi: 10.3389/fcimb.2022.884365. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35669117 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
